Mirena (Levonorgestrel)

Levonorgestrel, the active ingredient in Mirena, is a progestogen presented as a 52 mg intrauterine system (IUS) for intrauterine use. It provides highly effective, reversible contraception for up to five years, is also indicated for the management of heavy menstrual bleeding, and is suitable for women seeking a low‑maintenance contraceptive option.

GNH USA supplies Mirena as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide. The company adheres to stringent quality standards and provides regulatory documentation for global distribution.

Levonorgestrel in Mirena acts within the hormonal contraceptive and menstrual‑management pathway.

- Contraception (long‑term): Provides up to five years of highly effective pregnancy prevention. - Heavy menstrual bleeding: Reduces menstrual blood loss and can improve anemia associated with excessive bleeding.

Levonorgestrel delivered by Mirena may be associated with a range of adverse reactions, varying in frequency and severity.

Common Side Effects: - Irregular bleeding or spotting: Unpredictable bleeding patterns during the first months after insertion. - Amenorrhea: Absence of menstrual periods in some users after prolonged use. - Pelvic or abdominal cramping: Discomfort that may occur during or after insertion.

Serious or Rare Side Effects: - Uterine perforation: Rare injury to the uterine wall during insertion. - Device expulsion: Partial or complete loss of the IUS from the uterus. - Severe allergic reaction: Anaphylaxis or hypersensitivity requiring immediate medical attention.

Prior to Mirena insertion and during its use, several precautionary measures should be observed to ensure safety and effectiveness.

- Pregnancy testing: Confirm a negative pregnancy test before insertion. - Uterine evaluation: Assess for fibroids, septum, or other abnormalities that may affect placement. - Infection screening: Defer insertion if active pelvic infection is present. - Smoking status: Advise women over 35 who smoke to quit due to increased cardiovascular risk. - Follow‑up visits: Schedule periodic examinations to verify IUS position and address symptoms. - Store at room temperature: Keep the device in its original packaging, protect from moisture and direct sunlight.

Levonorgestrel released from Mirena can interact with other medicines that influence its metabolism or hormonal activity.

Major Interactions (Avoid): - Enzyme inducers (e.g., rifampin, carbamazepine, phenytoin): May markedly reduce levonorgestrel plasma levels and contraceptive efficacy. - Antifungal azoles (e.g., ketoconazole, itraconazole): Can increase levonorgestrel concentrations, potentially heightening hormonal side effects.

Moderate Interactions (Monitor Closely): - Certain antibiotics (e.g., tetracycline, metronidazole): Limited evidence of reduced efficacy; monitor for breakthrough bleeding. - Antiretroviral agents (e.g., efavirenz, nevirapine): May lower levonorgestrel levels; consider alternative contraception. - Herbal supplements (e.g., St. John’s wort): May induce metabolism and decrease effectiveness.